EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

4‐Octyl Itaconate Suppresses Virulence of Multidrug‐Resistant Avian Pathogenic Escherichia coli via Cysteine Alkylation of LuxS, Icl, and OmpA

Saqib Nawaz iD, Xiaoxian Liu iD, Haiyang Wang iD, Yaqin Tian iD, Jingwen Zhang iD, Wei Jiang iD, Xiangan Han iD, Song Xiangjun iD

Transboundary and Emerging Diseases · 2026

DOI: 10.1155/tbed/5663447 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transboundary and Emerging Diseases, 2026. Verfasst von Saqib Nawaz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Anhui Province Key Laboratory of Veterinary Pathobiology and Disease Control, College of Animal Science and Technology, Anhui Agricultural University…. Hauptthemen laut MEDLINE: Escherichia coli, Escherichia coli Infections, Poultry Diseases, Succinates. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Agriculture Applied Technology Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Avian pathogenic Escherichia coli (APEC) is the cause of avian colibacillosis, which leads to huge economic losses in poultry production worldwide, and presents significant zoonotic antimicrobial resistance (AMR) risk. Cell‐permeable itaconate derivatives exhibit dual antibacterial and immunomodulatory properties; however, they have not been systematically evaluated against APEC, and their underlying molecular mechanisms remain poorly defined for this pathogen. In the present study, we systematically explored the anti‐APEC therapeutic potential and mechanism of action of 4‐octyl itaconate (4‐OI) using an integrated approach of in vitro phenotypic, ex vivo macrophage, biochemical genetic, and dual in vivo infection models. In vitro phenotypic assays revealed that 400 μM 4‐OI significantly inhibited the growth of the clinical isolate O78‐type APEC94 and increased its susceptibility to physiological osmotic and acid–base stress (pH 5–7) and decreased the biofilm formation by 64%, swarming motility by 57%, macrophage adhesion by 42%, and cellular invasion by 35%. Ex vivo, 4‐OI showed a dose‐dependent inhibitory effect on the intracellular survival of APEC in RAW264.7 macrophages, with equivalent efficacy to tetracycline, and without any host cell cytotoxicity. Mechanistic qPCR confirmed that 4‐OI inhibits the transcription of five key virulence genes ( fimC , luxS , wza , iroN , and menB ) by 2.4–5.3‐fold. Further biochemical pull‐down, LC‐MS/MS, site‐directed cysteine mutation, and gene knockout/overexpression assays demonstrated that 4‐OI directly alkylates the conserved cysteine residues of LuxS, isocitrate lyase (Icl), and OmpA, thereby simultaneously disrupting bacterial quorum sensing, glyoxylate shunt metabolism, and outer membrane integrity. The virulence‐attenuating effect of 4‐OI was confirmed by metabolite complementation assays, which showed that glyoxylate and menaquinone biosynthesis are defective. In vivo therapeutic evaluation showed that 50 mg/kg 4‐OI could significantly suppress APEC‐induced mouse mortality from 87.5% to 12.5%, reduce bacterial loads in serum and all visceral tissues, and downregulated proinflammatory cytokines (IL‐1β and TNF‐α) to relieve over‐immune pathological damage. 50 mg/kg 4‐OI increased the survival of chicken embryos to 86.7% and reduced the bacterial loads in the allantoic fluids by 83% in poultry‐relevant specific pathogen‐free (SPF) chicken embryo models. Moreover, 4‐OI exhibited antibiofilm and antiadhesion activity against various epidemic APEC serotypes and clinical multidrug‐resistant isolates with no effect on the diversity or composition of chicken cecal microbiota. Collectively, our findings support 4‐OI as a safe alternative to conventional antibiotics for treating avian colibacillosis, acting via cysteine alkylation to repress multiple virulence‐ and metabolic‐related targets. This work establishes a multifaceted preclinical proof‐of‐concept dataset supporting further development of 4‐OI as an anti‐multi‐drug resistance (MDR) candidate agent; additional farm‐relevant in vivo trials will be required prior to real‐world application for safeguarding poultry health and global food safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Escherichia coliEscherichia coli InfectionsPoultry DiseasesSuccinatesAnti-Bacterial AgentsAnimalsVirulenceChickensDrug Resistance, Multiple, BacterialBacterial ProteinsCarbon-Sulfur LyasesAlkylationCysteineMiceIsocitrate Lyase

Stichwörter der Autor:innen

4-octyl itaconateAPECantimicrobial alternativeavian colibacillosiscysteine alkylationmetabolic disruptionpoultry gut microbiota safetyvirulence attenuation

Substanzen

SuccinatesAnti-Bacterial AgentsBacterial ProteinsCarbon-Sulfur LyasesLuxS protein, Bacteriaitaconic acidCysteineIsocitrate Lyase

Autor:innen und Institutionen

  • Anhui Province Key Laboratory of Veterinary Pathobiology and Disease Control, College of Animal Science and Technology, Anhui Agricultural University, Hefei, 230036, China, ahau.edu.cn.
  • Joint Research Center for Food Nutrition and Health of IHM, Anhui Agricultural University, Hefei, China, ahau.edu.cn.
  • Anhui Province Engineering Laboratory for Animal Food Quality and Bio-safety, College of Animal Science and Technology, Anhui Agricultural University, Hefei, 230036, China, ahau.edu.cn.
  • Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 518 Ziyue Road, Minhang, Shanghai, 200241, China, caas.cn.
  • Key Laboratory of Agri-products Quality and Biosafety, Anhui Agricultural University, Ministry of Education, Hefei, 230036, China, ahau.edu.cn.

ORCID-Profile: Saqib Nawaz, Xiaoxian Liu, Haiyang Wang, Yaqin Tian, Jingwen Zhang, Wei Jiang, Xiangan Han, Song Xiangjun

Förderung

  • National Natural Science Foundation of China
  • Shanghai Agriculture Applied Technology Development Program

Zitieren

APA

Nawaz, S., Liu, X., Wang, H., Tian, Y., Zhang, J., Jiang, W., Han, X., & Xiangjun, S. (2026). 4‐Octyl Itaconate Suppresses Virulence of Multidrug‐Resistant Avian Pathogenic Escherichia coli via Cysteine Alkylation of LuxS, Icl, and OmpA. Transboundary and Emerging Diseases. https://doi.org/10.1155/tbed/5663447

Vancouver

Nawaz S, Liu X, Wang H, Tian Y, Zhang J, Jiang W, et al. 4‐Octyl Itaconate Suppresses Virulence of Multidrug‐Resistant Avian Pathogenic Escherichia coli via Cysteine Alkylation of LuxS, Icl, and OmpA. Transboundary and Emerging Diseases. 2026. doi:10.1155/tbed/5663447

BibTeX
@article{Nawaz2026,
  author = {Nawaz, Saqib and Liu, Xiaoxian and Wang, Haiyang and Tian, Yaqin and Zhang, Jingwen and Jiang, Wei and Han, Xiangan and Xiangjun, Song},
  title = {4‐Octyl Itaconate Suppresses Virulence of Multidrug‐Resistant Avian Pathogenic Escherichia coli via Cysteine Alkylation of LuxS, Icl, and OmpA},
  journal = {Transboundary and Emerging Diseases},
  year = {2026},
  doi = {10.1155/tbed/5663447}
}
Kostenlos starten →